Skip to main content
SpringerLink
Log in

Gastroenteropancreatic endocrine tumors

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

AA:

amino acid

ACTH:

adrenocorticotropic hormone

ADH:

antidiuretic hormone, vasopressin

APUD:

amine precursor uptake and decarboxylation

CCK:

cholecystokinin

CNS:

central nervous system

CT:

calcitonin

ENS:

enteric nervous system

FSH:

follicle-stimulating hormone

GABA:

gamma-aminobutyric acid

GEP:

gastroenteropancreatic

GH:

growth hormone

GHRH:

growthhormone releasing hormone, also GRF

GHRIH:

growth-hormone release-inhibiting hormone, somatostatin, also SRIF

GI:

gastrointestinal

GIP:

gastric inhibitory peptide, renamed glucose-dependent insulinotropic peptide

Gn:

gonadotropin(s)

GnRH:

gonadotropin releasing hormone, also LHRH

GRF:

growth-hormone releasing factor, also GHRH

HCG:

human chorionic gonadotropin

5-HIAA:

5-hydroxyindoleacetic acid

5-HT:

5-hydroxytryptamine, serotonin

5-HTP:

5-hydroxytryptophan

ICC:

immunocytochemistry

LHRH:

luteinizing-hormone releasing hormone, also GnRH

MEA:

multiple endocrine adenomatosis, also MEN

MEN:

multiple endocrine neoplasia, also MEA

MEN I:

multiple endocrine neoplasia of type I

MSH:

melanocyte-stimulating hormone

MW:

molecular weight

NSE:

neurone-specific enolase

NT:

neurotransmitter

PHI:

peptide histidine-isoleucine

PHM:

peptide histidine-methionine

PNS:

peripheral nervous system

PP:

pancreatic polypeptide

PRL:

prolactin

PTH:

parathormone

PZ:

pancreozymin

RIA:

radioimmunoassay

SRIF:

somatotropin release-inhibiting factor, somatostatin, also GHRIH

TRH:

thyrotropin-releasing hormone

TSH:

thyroid-stimulating hormone

VIP:

vasoactive intestinal peptide

ZES:

Zollinger-Ellison syndrome

References

  1. Adrian TE, Barnes AJ, Long RG, O'Shaughnessy DJ, Brown MR, Rivier J, Vale W, Blackburn AM, Bloom SR (1981) The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man. J clin Endocr Metab 53:675–681

    Google Scholar 

  2. Adrian TE, Besterman HS, Mallinson CN, Czaykowska WM, Bloom SR (1977) Studies on the release of pancreatic polypeptide and its relationship to pancreatic exocrine function. J Endocr 75:35P-36P

    Google Scholar 

  3. Alberti KGMM, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K, Ørskov H (1973) Inhibition of insulin secretion by somatostatin. Lancet 2:1299–1301

    Google Scholar 

  4. Althoff PH, Boettger B, Rosak C, Neufeld M, Lacey F, Knigge H, Magnet W, Jungman E, Schöffling K (1984) Influence of a long-acting somatostatin analogue (SMS 201-995) in acromegalic patients. Acta endocr (Kbh) 105 (Suppl 264):29, abstract 36

    Google Scholar 

  5. Alumets, J, Ekelund G, Håkanson R, Ljungberg O, Ljungqvist U, Sundler F, Tibblin S (1978) Jejunal endocrine tumour composed of somatostatin and gastrin cells and associated with duodenal ulcer disease. Virchows Arch A path Anat 378:17–22

    Google Scholar 

  6. Andrew A (1982) The APUD concept: Where has it led us? Br med Bull 38:221–225

    Google Scholar 

  7. Aoyagi T, Summerskill WH (1966) Gastric secretion with ulcerogenic islet cell tumor. Importance of basal acid output. Arch intern Med 117:667–672

    Google Scholar 

  8. Arbol JL del, Jimenez-Alonso J, Garcia Romero E, Osorio J, Peña Yañez A (1979) Hiperinsulinismo por hiperplasia de células beta pancreáticas. Valor de la determinación de proinsulina y del test de la somatostatina-tolbutamida. Rev clin esp 152:239–242

    Google Scholar 

  9. Arimura A, Sato H, Dupont A, Nishi N, Schally AV (1975) Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science 189:1007–1009

    Google Scholar 

  10. Arnold R, Lankisch PG (1980) Somatostatin and the gastrointestinal tract. Clinics Gastroenterol 9:733–753

    Google Scholar 

  11. Axelrod L, Busch MA, Hirsch HJ, Loo SWH (1981) Malignant somatostatinoma: clinical features and metabolic studies. J clin Endocr Metab 52:886–896

    Google Scholar 

  12. Ballard HS, Fame B, Hartsock RJ (1964) Familial multiple endocrine adenoma-peptic ulcer complex. Medicine (Balt) 43:481–516

    Google Scholar 

  13. Banting FG, Best CH (1922) The internal secretion of the pancreas. J Lab clin Med 7:251–266

    Google Scholar 

  14. Barnes AJ, Long RG, Adrian TE, Vale W, Brown MR, Rivier JE, Hanley J, Ghatei MA, Sarson DL, Bloom SR (1981) Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man. Clin Sci 61:653–656

    Google Scholar 

  15. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140

    Google Scholar 

  16. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1983) Structure-activity relationships of highly potent and specific octapeptide analogues of somatostatin. In: Bláha K, Malon P (eds) Peptides 1982. Walter de Gruyter, Berlin New York, pp 583–588

    Google Scholar 

  17. Bayliss WM, Starling EH (1902) The mechanism of pancreatic secretion. J Physiol (Lond) 28:325–353

    Google Scholar 

  18. Becker SW, Kahn D, Rothman S (1942) Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syph 45:1069–1080

    Google Scholar 

  19. Berchtold P, Berger M, Wiegelmann W, Cüppers HJ, Grüneklee D, Reinwein D, Gries FA, Zimmermann H (1976) Serum insulin suppression by somatostatin, diazoxide, and phenytoin in insulinoma patients. 5th int Congr Endocrinology, Hamburg 1976 (Abstract 229)

  20. Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries A, Münterfering H, Sailer R, Zimmermann H, Orci L (1983) Functional and morphologic characterization of human insulinomas. Diabetes 32:921–931

    Google Scholar 

  21. Bethge N, Diel F, Usadel KH (1982) Somatostatin — a regulatory peptide of clinical importance. J clin Chem clin Biochem 20:603–613

    Google Scholar 

  22. Bishop AE, Polak JM, Facer P, Ferri GL, Marangos PJ, Pearse AGE (1982) Neuron specific enolase: a common marker for the endocrine cells and innervation of the gut and pancreas. Gastroenterology 83:902–915

    Google Scholar 

  23. Blackburn AM, Bryant MG, Adrian TE, Bloom SR (1981) Pancreatic tumours produce neurotensin. J clin Endocr Metab 52:820–822

    Google Scholar 

  24. Bloom SR, Ch'ng JLC, Wood SM, Kraenzlin M, Williams SJ (1984) Effect of chronic administration of a long-acting somatostatin analogue on glucose homeostasis. Diabetologia 27:258A

    Google Scholar 

  25. Bloom SR, Christofides ND, Delamarter J, Buell G, Kawashima E, Polak JM (1983) Diarrhoea in VIPoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene. Lancet 2:1163–1165

    Google Scholar 

  26. Bloom SR, Mortimer CH, Thorner MO, Besser GM, Hall R, Gomez-Pan A, Roy VM, Russell RCG, Coy DH, Kastin AJ, Schally AV (1974) Inhibition of gastrin and gastricacid secretion by growth-hormone release-inhibiting hormone. Lancet 2:1106–1109

    Google Scholar 

  27. Bloom SR, Polak JM (1980) Glucagonomas, VIPomas and somatostatinomas. Clinics Endocr Metab 9:285–297

    Google Scholar 

  28. Bloom SR, Polak JM, Pearse AGE (1973) Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet 2:14–16

    Google Scholar 

  29. Bloom SR, Ralphs DN, Besser GM, Hall R, Coy DH, Kastin AJ, Schally AV (1975) Effect of somatostatin on motilin levels and gastric emptying. Gut 16:834

    Google Scholar 

  30. Bloomgarden ZT, Sundell H, Rogers LW, O'Neill JA, Liljenquist JE (1980) Treatment of intractable neonatal hypoglycemia with somatostatin plus glucagon. J Pediat 96:148–151

    Google Scholar 

  31. Bonfils S, Landor JH, Mignon M, Hervoir P (1981) Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. Ann Surg 194:692–697

    Google Scholar 

  32. Bonfils S, René E, Pignal F, Rambaud JC (1979) Rebound effect after somatostatin treatment in Verner-Morrison syndrome. Lancet 2:476

    Google Scholar 

  33. Bonnici F, Millar RP, White P (1984) Pre-operative management of neonatal nesidioblastosis with somatostatin-28. 7th int Congr Endocrinology, Quebec 1984 (Abstract 69, p 295)

  34. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79

    Google Scholar 

  35. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann intern Med 79:101–107

    Google Scholar 

  36. Burnstock G (1976) Do some nerve cells release more than one transmitter? Neuroscience 1:239–248

    Google Scholar 

  37. Burnstock G (1981) Physiology of gastrointestinal nerves. In: Bloom SR, Polak JM (eds) Gut Hormones, 2nd ed. Churchill Livingstone, Edinburgh London Melbourne New York, pp 482–486

    Google Scholar 

  38. Caplan RH, Koob L, Abellera RM, Pagliara AS, Kovacs K, Randall RV (1978) Cure of acromegaly by operative removal of an islet cell tumor of the pancreas. Am J Med 64:874–882

    Google Scholar 

  39. Cheek RC, Wilson H (1970) Carcinoid tumors. Curr Probl Surg 7:4–31

    Google Scholar 

  40. Ch'ng JLC, Williams SJ, Bloom SR (1984) Chronic treatment of gut hormone producing tumours. Abstract, 5th int Symp Gastrointest Hormones, Rochester, Mn 1984

  41. Christensen SE, Hansen AP, Lundbaek K, Ørskov H, Seyer-Hansen K (1975) Somatostatin and insulinoma. Lancet 1:1426

    Google Scholar 

  42. Ciaccio C (1906) Sur une nouvelle espèce cellulaire dans les glandes de Lieberkühn. CR Soc Biol (Paris) 60:76–77

    Google Scholar 

  43. Costa M, Furness JB (1982) Neuronal peptides in the intestine. Br med Bull 38:247–252

    Google Scholar 

  44. Creutzfeld W, Ebert R (1978) Release of gastric inhibitory peptide (GIP) to a test meal under normal and pathological conditions in man. Proc 9th Congr int Diabetes Fed, New Delhi 1976. Excerpta Medica, Amsterdam, pp 63–75 (Cited by Arnold and Lankisch, loc cit)

    Google Scholar 

  45. Curnow RT, Carey RM, Taylor A, Johanson A, Murad F (1975) Somatostatin inhibition of insulin and gastrin secretion in pancreatic islet-cell carcinoma. New Engl J Med 292:1385–1386

    Google Scholar 

  46. Davis GR, Camp RC, Raskin P, Krejs GJ (1980) Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome. Gastroenterology 78:346–349

    Google Scholar 

  47. Dharmsathaphorn, K, Sherwin RS, Binder HJ, Dobbins JW (1978) Somatostatin inhibits intestinal fluid secretion. Clin Res 26:496A

    Google Scholar 

  48. Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J (1980) Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann intern Med 92:68–69

    Google Scholar 

  49. Dockray GJ (1976) Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264:568–570

    Google Scholar 

  50. Doepfner W, Briner U, Marbach P (1983) Effects on blood glucose in rats and rhesus monkeys of a new highly active analogue of somatostatin: SMS 201-995. Acta endocr 103 (Suppl 256):79

    Google Scholar 

  51. Dubois MP (1975) Immunoreactive somatostatin is present in discrete cells of the endocrine pancreas. Proc nat Acad Sci USA 72:1340–1343

    Google Scholar 

  52. Edkins JS (1905) On the chemical mechanism of gastric secretion. Proc roy Soc Ser B 76:376

    Google Scholar 

  53. Efendić S, Lins PE, Sigurdsson G, Ivemark B, Granberg PO, Luft R (1976) Effect of somatostatin on basal and glucose induced insulin release in five patients with hyperinsulinaemia. Acta endocr (Kbh) 81:525–529

    Google Scholar 

  54. Ellison EH, Wilson SD (1964) The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 160:512–530

    Google Scholar 

  55. Erspamer V, Asero B (1952) Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169:800–801

    Google Scholar 

  56. Euler US von, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol (Lond) 72:74–87

    Google Scholar 

  57. Fahrenkrug J, Emson PC (1982) Vasoactive intestinal polypeptide: functional aspects. Br med Bull 38:265–270

    Google Scholar 

  58. Fallucca F, Delle Fave G, Giangrande L, Del Balzo P, De Magistris L, Carratù R (1981) Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome. J endocr Invest 4:451–453

    Google Scholar 

  59. Fallucca F, Mirabella C, Tamburrano G, Gambardella S, Aufieri G, Barbetti F, Andreani D (1979) Effects of somatostatin on insulin and glucagon in patients with insulinoma. J endocr Invest 2:257–260

    Google Scholar 

  60. Feyrter F (1938) Über diffuse endokrine epitheliale Organe. JA Barth, Leipzig

    Google Scholar 

  61. Floyd JC Jr, Fajans SS, Pek S, Chance RE (1977) A newly recognized pancreatic polypeptide; plasma levels in health and disease. Rec Progr Hormone Res 33:519–570

    Google Scholar 

  62. Fox PS, Hoffmann JW, Wilson SD, DeCosse JJ (1974) Surgical management of the Zollinger-Ellison syndrome. Surg Clin North Am 54:395–407

    Google Scholar 

  63. Friesen SR (1982) The APUD syndromes. Progr clin Cancer 8:75–87

    Google Scholar 

  64. Frohman LA, Szabo M, Berelowitz M, Stachura ME (1980) Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. J clin Invest 65:43–54

    Google Scholar 

  65. Frölich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D (1978) The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. New Engl J Med 299:1055–1057

    Google Scholar 

  66. Frölich JC, Reimann I, Rabin D, Bloomgarden ZT, Bloom SR, Oates J, Müller WA (1979) Wirkung von Somatostatin beim Carcinoid- und Verner-Morrison-Syndrom. Verh dt Ges inn Med 85:174–175

    Google Scholar 

  67. Furness JB, Costa M (1982) Identification of gastrointestinal neurotransmitters. In: Bertaccini G (ed) Mediators and Drugs in Gastrointestinal Motility I, Vol 59/I of Handbook of Experimental Pharmacology. Springer, Berlin Heidelberg New York, pp 383–460

    Google Scholar 

  68. Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S (1977) “Somatostatinoma”: a somatostatin-containing tumor of the endocrine pancreas. New Engl J Med 296:963–967

    Google Scholar 

  69. Gerich JE (1980) The pharmacology and potential clinical applications of somatostatin and its analogues. In: Briggs M, Corbin A (eds) Progress in Hormone Biochemistry and Pharmacology, Vol 1. Eden Press/MTP Press, Lancaster, pp 55–147

    Google Scholar 

  70. Gerich JE, Lorenzi M, Schneider V, Karam JH, Rivier J, Guillemin R, Forsham PH (1974) Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. New Engl J Med 291:544–547

    Google Scholar 

  71. Ginsberg-Fellner F, Rayfield EJ (1980) Metabolic studies in a child with a pancreatic insulinoma. Am J Dis Child 134:64–67

    Google Scholar 

  72. Go VLW, Michener S, Roddy D, Koch M (1984) Clinical relevance of regulatory gastrointestinal peptides. Clin Biochem 17:82–88

    Google Scholar 

  73. Godwin DJ (1975) Carcinoid tumors. An analysis of 2837 cases. Cancer 36:560–569

    Google Scholar 

  74. Gosset A, Masson P (1914) Tumeurs endocrines de l'appendice. Presse méd 22:237–240

    Google Scholar 

  75. Gottesman IS, Mandarino LJ, Gerich JE (1982) Somatostatin: its role in health and disease. In: Cohen MP, Foà PP (eds) Special Topics in Endocrinology and Metabolism, Vol 4. Alan R. Liss, New York, pp 177–243

    Google Scholar 

  76. Greenberg GR, McCloy RF, Adrian TE, Chadwick VS, Baron JH, Bloom SR (1978) Inhibition of pancreas and gallbladder by pancreatic polypeptide. Lancet 2:1280–1282

    Google Scholar 

  77. Gregory RA, Tracy HJ, French JM, Sircus W (1960) Extraction of a gastrin-like substance from a pancreatic tumour in a case of Zollinger-Ellison syndrome. Lancet 1:1045–1048

    Google Scholar 

  78. Grobecker H (1983) Transmitter-peptide coexistence in the central nervous system. Eur Neurol 22 (Suppl 1):38–46

    Google Scholar 

  79. Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly AS, Mortimer CH, Phenekos C, Tunbridge WMG, Weightman D (1973) Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 2:581–584

    Google Scholar 

  80. Harper AA, Raper HS (1943) Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine. J Physiol (Lond) 102:115–125

    Google Scholar 

  81. Heidenhain R (1870) Untersuchungen über den Bau der Labdrüsen. Arch mikr Anat 6:368–406

    Google Scholar 

  82. Heitz PU, Staub JJ (1981) Paraneoplastische endokrine Syndrome. In: Pathologie der endokrinen Organe, spezielle pathologische Anatomie Bd. 14. Springer, Berlin Heidelberg New York, pp 1205–1272

    Google Scholar 

  83. Heitz PU, Steiner H (1981) Pluriglanduläre endokrine Regulationsstörungen. In: Pathologie der endokrinen Organe, spezielle pathologische Anatomie Bd. 14. Springer, Berlin Heidelberg New York, pp 1137–1203

    Google Scholar 

  84. Hirsch HJ, Loo S, Evans N, Crigler JF Jr, Filler RM, Gabbay KH (1977) Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin. New Engl J Med 296:1323–1326

    Google Scholar 

  85. Hökfelt T, Johansson O, Ljungdahl A, Lundberg JM, Schultzberg M (1980) Peptidergic neurones. Nature 284:515–521

    Google Scholar 

  86. Holst JJ (1979) Gut endocrine tumour syndromes. Clinics Endocr Metab 8:413–432

    Google Scholar 

  87. Ihász M, Balázs M, Csillag A, Szabó K, Horrai F (1982) Carcinoid tumors of the gastrointestinal tract. Acta chir Acad Sci hung 23/2:95–115

    Google Scholar 

  88. Isenberg JI, Walsh JH, Grossman MI (1973) Zollinger-Ellison syndrome. Gastroenterology 65:140–165

    Google Scholar 

  89. Isler P, Hedinger C (1953) Metastasierendes Dünndarmcarcinoid mit schweren, vorwiegend das rechte Herz betreffenden Klappenfehlern und Pulmonalstenose — ein eigenartiger Symptomenkomplex? Schw med Wochenschr 83:4–7

    Google Scholar 

  90. Ivy AC, Oldberg EA (1928) A hormone mechanism for gall bladder contraction and evacuation. Am J Physiol 86:599–613

    Google Scholar 

  91. Jacobelli A, Agostino A, Altomonte G (1984) Sindromi endocrine paraneoplastiche. Clin Ter (Roma) 108:245–253

    Google Scholar 

  92. Jaffe BM, Condon S (1976) Prostaglandins E and F in endocrine diarrheagenic syndromes. Ann Surg 184:516–524

    Google Scholar 

  93. Jorpes JE, Mutt V, Toczko K (1964) Further purification of cholecystokinin and pancreozymin. Acta chem scand 18:2408–2410

    Google Scholar 

  94. Kahn CR, Bhatena SJ, Recant L, Rivier J (1981) Use of somatostatin and somatostatin analogs in a patient with a glucagonoma. J clin Endocr Metab 53:543–549

    Google Scholar 

  95. Kaneko H, Yanaihara N, Ito S, Kusumoto Y, Fujita T, Ishikawa S, Sumida T, Sekiya M (1979) Somatostatinoma of the duodenum. Cancer 44:2273–2279

    Google Scholar 

  96. Kimball CP, Murlin JR (1923) Aqueous extracts of pancreas. III. Some precipitation reactions of insulin. J biol Chem 58:337–341

    Google Scholar 

  97. Kimmel JR, Pollock HG, Hazelwood RL (1968) Isolation and characterization of chicken insulin. Endocrinology 83:1323–1330

    Google Scholar 

  98. Kitson HF, McCrossin RB, Jimenez M, Middleton A, Silink M (1980) Somatostatin treatment of insulin excess due to beta-cell adenoma in a neonate. J Pediat 96:145–148

    Google Scholar 

  99. Klapdor R (1980) Effects of somatostatin on bronchial constriction in a patient with carcinoid syndrome. New Engl J Med 303:464

    Google Scholar 

  100. Klöppel G (1981) Endokrines Pankreas und Diabetes mellitus. In: Pathologie der endokrinen Organe, spezielle pathologische Anatomie Bd. 14. Springer, Berlin Heidelberg New York, pp 523–728

    Google Scholar 

  101. Klöppel G, Heitz PU (1981) Die disseminierten (diffusen) endokrinen Zellen. In: Pathologie der endokrinen Organe, spezielle pathologische Anatomie Bd. 14. Springer, Berlin Heidelberg New York, pp 1079–1135

    Google Scholar 

  102. Koerker DJ, Ruch W, Chidekel E, Palmer J, Goodner CJ, Ensinck J, Gale CC (1974) Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184:482–484

    Google Scholar 

  103. Kraenzlin ME, Ch'ng JLC, Wood SM, Carr DH, Bloom SR (1985) Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88:185–187

    Google Scholar 

  104. Krejs GJ (1980) Effect of VIP infusion on water and ion transport in the human large intestine. Gastroenterology 78:1200

    Google Scholar 

  105. Krejs GJ, Fordtran JS, Bloom SR, Fahrenkrug J, Schaffalitzky de Muckadell OB, Fischer JE, Humphrey CS, O'Dorisio TM, Said SI, Walsh JH, Shulkes AA (1980) Effect of VIP infusion on water and ion transport in the human jejunum. Gastroenterology 78:722–727

    Google Scholar 

  106. Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor TAM, Unger RH (1979) Somatostatinoma syndrome. Biochemical, morphologic and clinical features. New Engl J Med 301:285–292

    Google Scholar 

  107. Krieger DT, Martin JB (1981) Brain peptides. New Engl J Med 304:876–885, 944–951

    Google Scholar 

  108. Kultschitzky N (1897) Zur Frage über den Bau des Darmkanals. Arch mikr Anat 49:7–35

    Google Scholar 

  109. Lanhans P, Clemens M, Schlake W, Bassewitz DB von (1979) Karzinoid und Karzinoidsyndrom. Med Klin 74:1721–1728

    Google Scholar 

  110. Larsson LI, Fahrenkrug J, Schaffalitzky de Muckadell O, Sundler F, Håkanson R, Rehfeld JF (1976) Localization of vasoactive intestinal peptide (VIP) to central and peripheral neurons. Proc nat Acad Sci USA 73:3197–3200

    Google Scholar 

  111. Larsson LI, Hirsch MA, Holst JJ, Ingemansson S, Kühl C, Lindkaer Jensen S, Lundqvist G, Rehfeld JF, Schwartz TW (1977) Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet 1:666–668

    Google Scholar 

  112. Launay JM, Tabuteau F, Haimart M, Ganem Y, Villette JM, Dreux C, Debous-Guillemin MC, Roseto A, Peries J (1983) The diffuse neuroendocrine (APUD) system. Biomed Pharmacother 37:322–328

    Google Scholar 

  113. Lembeck F (1953) 5-Hydroxytryptamine in a carcinoid tumour. Nature 172:910–911

    Google Scholar 

  114. Lennon J, Bloom SR, Sircus W (1978) Studies on blood levels of vasoactive inhibitory peptide (VIP) and pancreatic polypeptide (PP) and their relation to clinical behaviour in a case of Werner-Morrison syndrome. It J Gastroenterol 10:104–106

    Google Scholar 

  115. Lennon JR, Sircus W, Bloom SR, Mitchell SJ, Polak JM, Besser GM, Hall R, Coy DH, Kastin AJ, Schally AV (1975) Investigation of a recurrent vipoma. Gut 16:821–822

    Google Scholar 

  116. Lin TM, Chance RE (1972) Spectrum of gastrointestinal actions of a new bovine pancreatic polypeptide (BPP). Gastroenterology 62:852

    Google Scholar 

  117. Lins PE, Efendić S (1979) Responses of patients with insulinomas to stimulators and inhibitors of insulin release that have been linked with cyclic adenosine monophosphate. Diabetes 28:190–195

    Google Scholar 

  118. Long RG, Barnes AJ, Adrian TE, Mallinson CN, Brown MR, Vale W, Rivier JE, Christofides ND, Bloom SR (1979) Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet 2:764–767

    Google Scholar 

  119. Long RG, Bryant MG, Mitchell SJ, Adrian TE, Polak JM, Bloom SR (1981) Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal peptide (vipomas). Br med J 282:1767–1771

    Google Scholar 

  120. Long RG, Peters JR, Bloom SR, Brown MR, Vale W, Rivier JE, Grahame-Smith DG (1981) Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut 22:549–553

    Google Scholar 

  121. Long RG, Peters JR, O'Shaughnessy DJ, Grahame-Smith DG, Vale W, Rivier JE, Brown MR, Bloom SR (1980) Somatostatin administration in the carcinoid syndrome. Gastroenterology 78:1211

    Google Scholar 

  122. Lorenzi M, Gerich JE, Karam JH, Forsham PH (1975) Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool. J clin Endocr Metab 40:1121–1124

    Google Scholar 

  123. Lubetzki J, Guillausseau PJ, Binet O, Hautefeuille P, Galian A, Mundler O, Aron-Brunetière R, Timsit J, Warnet A (1981) Pseudoglucagonoma responsive to somatostatin. Lancet 2:316–317

    Google Scholar 

  124. Luft R, Efendić S, Hökfelt T, Johansson O, Arimura A (1974) Immunohistochemical evidence for the localization of somatostatin-like immunoreactivity in a cell population of the pancreatic islets. Med Biol 52:428–430

    Google Scholar 

  125. Mallet E, Menibus CH de, Basuyau JP, Brunelle P (1980) Hyperinsulinism in infants of diabetic mothers. Lancet 1:776–777

    Google Scholar 

  126. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B (1974) A glucagonoma syndrome. Lancet 2:1–5

    Google Scholar 

  127. Marco J, Hedo JA, Villanueva ML (1977) Inhibitory effect of somatostatin on human pancreatic polypeptide secretion. Life Sci 21:789–792

    Google Scholar 

  128. Marco J, Hedo JA, Villanueva ML (1977) Inhibition of glucagon-like immunoreactivity (GLI) secretion by somatostatin in man. J clin Endocr Metab 44:695–698

    Google Scholar 

  129. Marks IN, Bank S, Louw JH (1967) Islet cell tumor of the pancreas with reversible watery diarrhea and achlorhydria. Gastroenterology 52:695–708

    Google Scholar 

  130. Mårtensson H, Nobin A, Sundler F (1983) Carcinoid tumors in the gastrointestinal tract — analysis of 156 cases. Acta chir scand 149:607–616

    Google Scholar 

  131. Masson P (1914) La glande endocrine de l'intestin chez l'homme. CR Acad Sci (Paris) 158:59–61

    Google Scholar 

  132. Maton PN, O'Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarkey TB, Collen MJ, Gardner JD, Jensen RT (1985) Effect of a long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. New Engl J Med 312:17–21

    Google Scholar 

  133. Matsumoto KK, Peter JB, Schultze RG, Hakim AA, Franck PT (1966) Watery diarrhea and hypokalemia associated with pancreatic islet cell adenoma. Gastroenterology 50:231–242

    Google Scholar 

  134. Mayer G, Tillil H (1984) Effect of the somatostatin analog SMS 201–995 on GH- and PRL-secretion in patients with acromegaly. Acta endocr (Kbh) 105 (Suppl 264):30–31, abstract 38

    Google Scholar 

  135. McGavran MH, Unger RH, Recant L, Polk HC, Kilo C, Levin ME (1966) A glucagon-secreting alpha-cell carcinoma of the pancreas. New Engl J Med 274:1408–1413

    Google Scholar 

  136. McGuigan JE (1968) Gastric mucosal intracellular localization of gastrin by immunofluorescence. Gastroenterology 55:315–327

    Google Scholar 

  137. Mering I von, Minkowski O (1890) Diabetes mellitus nach Pankreasexstirpation. Arch exp Path Pharmakol 26:371–387

    Google Scholar 

  138. Merling F (1838) Anatomie pathologique de l'appendice du caecum. Expérience (Paris) 1:337

    Google Scholar 

  139. Mortimer CH, Tunbridge WMG, Carr D, Yeomans L, Lind T, Coy DH, Bloom SR, Kastin A, Mallinson CN, Besser GM, Schally AV, Hall R (1974) Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet 1:697–701

    Google Scholar 

  140. Oates JA, Melmon K, Sjoerdsma A, Gillespie L, Mason DT (1964) Release of a kinin peptide in the carcinoid syndrome. Lancet 1:514–517

    Google Scholar 

  141. Oberndorfer S (1907) Über die kleinen Dünndarmcarcinome. Verh dtsch path Ges 11:113–116

    Google Scholar 

  142. Oberndorfer S (1907) Karzinoide Tumoren des Dünndarms. Frankf Z Path 1:426

    Google Scholar 

  143. Ohneda A, Otsuki M, Fujiya H, Yaginuma N, Kokubo T, Ohtani H (1979) A malignant insulinoma transformed into a glucagonoma syndrome. Diabetes 28:962–969

    Google Scholar 

  144. Owyang C, Go VL (1980) Multiple hormone-secreting tumors of the gastrointestinal tract. In: Glass GBJ (ed) Gastrointestinal Hormones. Raven Press, New York, pp 741–748

    Google Scholar 

  145. Palkovits M (1984) Topography of chemically identified neurons in the central nervous system: progress in 1981–1983. In: Müller EE, MacLeod RM (eds) Neuroendocrine Perspectives, Vol 3. Elsevier, Amsterdam New York Oxford, pp 1–69

    Google Scholar 

  146. Patel YC, Zingg HH, Fitz-Patrick D, Srikant CB (1981) Somatostatin: some aspects of its physiology and pathophysiology. In: Bloom SR, Polak JM (eds) Gut Hormones, 2nd ed. Churchill Livingstone, Edinburgh London Melbourne New York, pp 339–349

    Google Scholar 

  147. Pearse AGE (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, histologic and pathologic implications of the concept. J Histochem Cytochem 117:303–313

    Google Scholar 

  148. Pearse AGE (1975) Neurocristopathy, neuroendocrine pathology and the APUD concept. Z Krebsforsch 84:1–18

    Google Scholar 

  149. Peart WS, Porter KA, Robertson JIS, Sandler M, Baldock E (1963) Carcinoid syndrome due to pancreatic-duct neoplasm secreting 5-hydroxytryptophan and 5-hydroxytryptamine. Lancet 1:239–243

    Google Scholar 

  150. Petrus M, Dutau G, Rochiccioli P (1981) Etude de la somatostatine dans un cas d'hyperinsulinisme sévère par nésidioblastose. Sem Hôp Paris 57:2036–2038

    Google Scholar 

  151. Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet 2:782–784

    Google Scholar 

  152. Polak JM, Bloom SR (1980) Neural and cellular origin of gastrointestinal hormonal peptides in health and disease. In: Glass GBJ (ed) Gastrointestinal Hormones. Raven Press, New York, pp 19–51

    Google Scholar 

  153. Polak JM, Bloom SR (1981) Organisation of gut peptidergic innervation. In: Bloom SR, Polak JM (eds) Gut Hormones, 2nd ed. Churchill Livingstone, Edinburgh London Melbourne New York, pp 487–494

    Google Scholar 

  154. Polak JM, Bloom SR (1983) Regulatory peptides: key factors in the control of bodily functions. Br med J 286:1461–1466

    Google Scholar 

  155. Polak JM, Pearse AGE, Grimelius L, Bloom SR, Arimura A (1975) Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet 1:1220–1222

    Google Scholar 

  156. Polak JM, Stagg B, Pearse AGE (1972) Two types of Zollinger-Ellison syndrome: immunofluorescent, cytochemical and ultrastructural studies of the antral and pancreatic gastrin cells in different clinical states. Gut 13:501–512

    Google Scholar 

  157. Prinz RA, Dorsch TR, Lawrence AM (1981) Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 76:125–131

    Google Scholar 

  158. Quatrini M, Basilisco G, Conte D, Bozzani A, Bardella MT, Bianchi PA (1983) Effects of somatostatin infusion in four patients with malignant carcinoid syndrome. Am J Gastroenterol 78:149–151

    Google Scholar 

  159. René E, Rigaud D, Mignon M, Bonfils S (1984) Syndrome de Zollinger-Ellison. Aspects thérapeutiques. Ann Méd interne 135:403–406

    Google Scholar 

  160. Rosell S, Rökaeus Å, Theodorsson-Norheim E (1983) The role of neurotensin in disease. Scand J Gastroenterol 18 (Suppl 82):59–67

    Google Scholar 

  161. Roth J, LeRoith D, Shiloach J, Rosenzweig JL, Lesniak MA, Havrankova J (1982) The evolutionary origin of hormones, neurotransmitters, and other extracellular chemical messengers. Implications for mammalian biology. New Engl J Med 306:523–527

    Google Scholar 

  162. Roti E, Ghinelli C, Bandini P, Del Rossi C, Emanuele R, Robuschi G, Gnudi A (1981) Effects of somatostatin in a case of severe hypoglycemia due to nesidioblastosis. J endocr Invest 209:209–212

    Google Scholar 

  163. Ruskoné A, René E, Chayvialle JA, Bonin N, Pignal F, Kremer M, Bonfils S, Rambaud JC (1982) Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27:459–466

    Google Scholar 

  164. Ruttman E, Klöppel G, Bommer G, Kiehn M, Heitz PU (1980) Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature. Virchows Arch A path Anat 388:51–67

    Google Scholar 

  165. Said SI (1981) VIP overview. In: Bloom SR, Polak JM (eds) Gut Hormones, 2nd ed. Churchill Livingstone, Edinburgh Lodnon Melbourne New York, pp 379–384

    Google Scholar 

  166. Said SI, Mutt V (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169:1217–1218

    Google Scholar 

  167. Sanders RJ, Axtell HK (1964) Carcinoids of the gastrointestinal tract. Surg Gynec Obstet 119:369–380

    Google Scholar 

  168. Sandler M, Snow PJD (1958) An atypical carcinoid tumour secreting 5-hydroxytryptophan. Lancet 1:137–140

    Google Scholar 

  169. Scharrer E, Scharrer B (1940) Secretory cells within the hypothalamus. Proc Ass Res nerv ment Dis 20:170–194

    Google Scholar 

  170. Schein PS, DeLellis RA, Kahn CR, Gorden P, Kraft AR (1973) Islet cell tumors: current concepts and management. Ann intern Med 79:239–257

    Google Scholar 

  171. Scheinberg P (1965) Observations on cerebral carbohydrate metabolism in man. Ann intern Med 62:367–371

    Google Scholar 

  172. Schlüter KJ, Neufeld M, del Pozo E, Marbarch P, Cramer H, Kerp L (1983) Studies in healthy volunteers of a new somatostatin analogue: SMS 201–995. 65th Annual Meeting of the Endocrine Society, San Antonio, Tx, 1983 (Abstract 527)

  173. Schultzberg M, Hökfelt T, Lundberg JM (1982) Coexistence of classical transmitters and peptides in the central and peripheral nervous systems. Br med Bull 38:309–313

    Google Scholar 

  174. Scuro LA, Lo Cascio V, Adami S, Galvanini G, Bianchi I, Cominacini L, Corgnati A (1976) Somatostatin inhibition of insulin secretion in insulin-producing tumors. Metabolism 25:603–609

    Google Scholar 

  175. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979) Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J clin Endocr Metab 48:50–53

    Google Scholar 

  176. Skamene A, Patel YC (1984) Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. Clin Endocr 20:555–564

    Google Scholar 

  177. Sohier J, Jeanmougin M, Lombrail P, Passa P (1980) Rapid improvement of skin lesions in glucagonomas with intravenous somatostatin infusion. Lancet 1:40

    Google Scholar 

  178. Sokoloff B (1968) Carcinoid and Serotonin. In: Allfrey VG et al. (eds) Recent Results in Cancer Research, Vol 15. Springer, Berlin Heidelberg New York

    Google Scholar 

  179. Solcia E, Capella C, Buffa R, Frigerio B, Usellini L, Fiocca R (1980) Morphological and functional classification of endocrine cells and related growths in the gastrointestinal tract. In: Glass GBJ (ed) Gastrointestinal Hormones. Raven Press, New York, pp 1–17

    Google Scholar 

  180. Stadil F (1980) Gastrinomas. In: Glass GBJ (ed) Gastrointestinal Hormones. Raven Press, New York, pp 729–739

    Google Scholar 

  181. Steiner DF, Oyer PE (1967) The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc nat Acad Sci USA 57:473–480

    Google Scholar 

  182. Tanaka K, Watabe T, Shimizu N, Horiuchi T, Nakamura K, Yoshida H (1984) Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma. Metabolism 33:728–733

    Google Scholar 

  183. Thompson JC, Marx M (1984) Gastrointestinal hormones. Curr Probl Surg 21/6:1–80

    Google Scholar 

  184. Thorson Å, Biörck G, Björkman G, Waldenström J (1954) Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis. A clinical and pathological syndrome. Am Heart J 47:795–817

    Google Scholar 

  185. Thulin L, Samnegård H, Tydén G, Long DH, Efendić S (1978) Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 2:43

    Google Scholar 

  186. Tiedemann K, Pritchard J, Long R, Bloom SR (1981) Intractable diarrhoea in a patient with vasoactive intestinal peptide-secreting neuroblastoma. Eur J Pediat 137:217–219

    Google Scholar 

  187. Tiengo A, Fedele D, Marchiori E, Nosadini R, Muggeo M (1976) Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin, and gastrin. Diabetes 25:408–412

    Google Scholar 

  188. Tilson D (1974) Carcinoid syndrome. Surg Clin North Am 54:409–423

    Google Scholar 

  189. Unger RH, Dobbs RE, Orci L (1978) Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Ann Rev Physiol 40:307–343

    Google Scholar 

  190. Veber DF, Holly FW, Nutt RF, Bergstrand SJ, Brady SF, Hirschmann R, Glitzer MS, Saperstein R (1979) Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature 280:512–514

    Google Scholar 

  191. Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25:374–380

    Google Scholar 

  192. Vinik AI, Achem-Karam S, Owyang C (1982) Gastrointestinal hormones in clinical medicine. In: Cohen MP, Foà PP (eds) Special Topics in Endocrinology and Metabolism, Vol 4. Alan R Liss, New York, pp 93–138

    Google Scholar 

  193. Wahren J, Felig P (1976) Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet 2:1213–1216

    Google Scholar 

  194. Welbourn RB, Polak JM, Bloom SR, Pearse AGE, Galland RB (1978) Apudomas of the pancreas. In: Bloom SR (ed) Gut Hormones. Churchill Livingstone, Edinburgh London New York, pp 561–569

    Google Scholar 

  195. Welbourn RB, Wood SM, Polak JM, Bloom SR (1981) Pancreatic endocrine tumours. In: Bloom SR, Polak JM (Eds) Gut Hormones, 2nd ed. Churchill Livingstone, Edinburgh London Melbourne New York, pp 547–554

    Google Scholar 

  196. Werder K von, Losa M, Müller OA, Schweiberer L, Fahlbusch R, del Pozo E (1984) Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue. Lancet 2:282–283

    Google Scholar 

  197. Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16:363–371

    Google Scholar 

  198. Wilder RM, Allan FN, Power MH, Robertson HE (1927) Carcinoma of the islands of the pancreas; hyperinsulinism and hypoglycemia. J am med Ass 89:348–355

    Google Scholar 

  199. Wilkinson DS (1971) Necrolytic migratory erythema with pancreatic carcinoma. Proc roy Soc Med 64:1197–1198

    Google Scholar 

  200. Williams ED, Sandler M (1963) The classification of carcinoid tumors. Lancet 1:238–239

    Google Scholar 

  201. Williams NS, Cooper JC, Axon ATR, King RFGJ, Barker M (1984) Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br med J 289:1027–1028

    Google Scholar 

  202. Wood SM, Bloom SR (1982) Glucagon and gastric secretion by a pancreatic tumour and its metastases. J roy Soc Med 75:42–44

    Google Scholar 

  203. Wood SM, Kraenzlin ME, Bloom SR (1983) New somatostatin analogue for home treatment of endocrine tumours. Gut 24:A984-A985

    Google Scholar 

  204. Wood SM, Polak JM, Bloom SR (1983) Gut hormone secreting tumours. Scand J Gastroenterol 82 (Suppl):165–179

    Google Scholar 

  205. Zollinger RM, Ellison EC, Fabri PJ, Johnson J, Sparks J, Carey LC (1980) Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal. Ann Surg 192:422–430

    Google Scholar 

  206. Zollinger RM, Ellisson EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709–728

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmazeutisches Departement, Klinische Forschung, Sandoz AG, Basel

    C. Weil

Authors
  1. C. Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weil, C. Gastroenteropancreatic endocrine tumors. Klin Wochenschr 63, 433–459 (1985). https://doi.org/10.1007/BF01731493

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731493

Keywords

Search

Navigation